1264P - Clinicopathologic features of never-smoking women lung cancer (WLC): a review from the Spanish WORLD07 database

Date 29 September 2012
Event ESMO Congress 2012
Session Poster presentation I
Topics Non-Small-Cell Lung Cancer, Metastatic
Cancer Aetiology, Epidemiology, Prevention
Presenter javier De Castro
Authors J. De Castro1, D. Isla Casado2, M. Provencio Pulla3, M. Majem Tarruella4, N. Vinolas Segarra5, E. Felip6, A. Artal-Cortes7, R. García-Campelo8, M. Domine9, P. Garrido Lopez10
  • 1Medical Oncology, Hospital Universitario La Paz, 28046 - madrid/ES
  • 2Oncology Service, Hospital Clínico Universitario Lozano Blesa, Zaragoza/ES
  • 3Oncology, Hospital Universitario Puerta de Hierro Majadahond, 28222 - Majadahonda/ES
  • 4Medical Oncology, Hospital de la Santa Creu i Sant Pau, 08041 - Barcelona/ES
  • 5Hospital Clinic y Provincial de Barcelona, ES-08036 - Barcelona/ES
  • 6Oncologia Médica, Vall d`Hebron University Hospital Institut d'Oncologia, 08035 - Barcelona/ES
  • 7Servicio De Oncologia Medica, Hospital Miguel Servet, ES-50009 - Zaragoza/ES
  • 8Medical Oncology, Complexo Hospitalario Universitario de A Coruña, La Coruña/ES
  • 9Oncology, Fundación Jiménez Díaz, Madrid/ES
  • 10Hospital Ramon y Cajal, ES-28034 - Madrid/ES



Lung cancer in never-smoker appears to be a distinct entity from lung cancer in smoker, with specific molecular characteristics and potential different treatment. Several factors like hormonal, environmental, genetic, pre-existing lung diseases, and virus, may play etiologic roles, and an in-depth understanding of them is needed. So, new clinicopathologic aspects of never-smoking WLC should be very important to know the biology of this tumoral disease.


Information has been extracted from WORLD07 database, a prospective, from 32 Spanish centers, epidemiologic female-specific lung cancer e-database performed by ICAPEM, an association to research WLC.


From October 2007 to October 2011, 539 newly diagnosed never-smoking WLC were included in World07 database (39.3% of 1371 patients(p). P characteristics are: median age 71.1 years(y) (range: 22-91). Previous history of cancer (%): 13(breast, lung, cervix: 41.4,5.7,2.9). Gynecological features: median age of menarche 13y, Postmenopausal 88.9%, median age of menopause 49y. Median age of first child 26.4y Children: 91.2% (median: 2.3). Oral contraceptive: 11.9%. HRT: 5.2%. Tobacco exposure: Second-hand smokers: 40%, work-exposure 17.1%, home-exposure 88.8%. Obesity: 16.3%. Familiar history of cancer: 39.9% (lung cancer 29.8%).Lung cancer histology (%): adenocarcinoma/BAC/squamous/large cell/SCLC/others: 69.2/6.8/5.7/5.0/3.8/3.8. EGFR mutated p (268 p analized): 55.5%, exon 19/20/21(%): 61.1/7.4/36.9. TNM NSCLC I/II/III/IV (%): 14/3.3/19.8/60.3. Treatment: EGFR-TKI in p harboring EGFR mutations stage IV (1st-/2nd-line)(%): 51.7/15.4; stage IV NSCLC(1st-line)(%): platinum-based chemotherapy 42.5, combinations with bevacizumab 2.9. Overall survival: median 27 months (m), 1/2-y(%) 74.8/55.2; stage IV NSCLC: median 20.5m, 1/2-y(%) 67/46; EGFR mutated p: median 27.3m, 1/2-y(%) 75/54.3.


Never-smoking WLC represents 39% of Spanish World07 database. The high incidence of adenocarcinoma histology (69.2%) and EGFR mutated tumors suggests a different clinical and genetic profiling and recommend a different treatment approach for this group of patients.


All authors have declared no conflicts of interest.